ACADIA Pharmaceuticals Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ACADIA Pharmaceuticals Inc.
Vertex and partner CRISPR Therapeutics hope CDX001 can offer a single-use curative regimen for sickle cell disease and beta thalassemia patients. A regulatory filing is possible within 18-24 months.
Biotronik is touting successful clinical trial results with its Orsiro sirolimus-eluting coronary stent while continuing to develop a resorbable stent.
The developers of eleven new drugs could learn this week whether the European Medicines Agency will set them on course for pan-EU marketing approval.
Although 2020 was the best year ever for Swiss biotech financing activities, no domestic IPOs were launched by the sector. But introducing the SPAC might change that.
- Other Names / Subsidiaries
- Receptor Technologies
- CerSci Therapeutics